Literature DB >> 29592972

Drug-induced movement disorder and confusion associated with duloxetine.

Sarah Hasan Siddiqui1, Nadeem Ahmed Memon1, Ravi Shanker1.   

Abstract

A 60-year-old woman with major depressive disorder, developed high blood pressure, confusion and dyskinesias of face, neck and jaw, following an increase in her dose of duloxetine. Routine blood tests including toxic, infective and metabolic workup were unremarkable. Cerebrospinal fluid analysis and electroencephalogram were also normal. MRI brain showed bilaterally symmetrical diffusion-restricted areas in deep cerebral white matter. Duloxetine was held on suspicion of drug adverse effect. She had complete resolution of symptoms within 48 hours and resolution of MRI brain changes over 6 weeks. Serotonin norepinephrine reuptake inhibitors such as duloxetine may have the potential to cause drug-induced movement disorders, confusion and high blood pressure and should be used cautiously especially in elderly. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  hypertension; neurology (drugs and medicines); unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 29592972      PMCID: PMC5878391          DOI: 10.1136/bcr-2016-216746

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  24 in total

1.  Akathisia and abnormal movements of the upper extremities with venlafaxine and methimazole.

Authors:  Jean Ng; Randy A Sansone; Stephen McDonald
Journal:  Gen Hosp Psychiatry       Date:  2008-11-17       Impact factor: 3.238

Review 2.  Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review.

Authors:  Paramananthan Mariappan; Ammar Alhasso; Zoe Ballantyne; Adrian Grant; James N'Dow
Journal:  Eur Urol       Date:  2006-09-15       Impact factor: 20.096

3.  Movement disorders in patients taking anticonvulsants.

Authors:  C Zadikoff; R P Munhoz; A N Asante; N Politzer; R Wennberg; P Carlen; A Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

4.  Treatment with duloxetine in adults and the incidence of cardiovascular events.

Authors:  Fei Xue; Indiana Strombom; Bruce Turnbull; Shao Zhu; John Seeger
Journal:  J Clin Psychopharmacol       Date:  2012-02       Impact factor: 3.153

5.  Neuroleptic malignant syndrome after venlafaxine.

Authors:  S R Nimmagadda; D H Ryan; S L Atkin
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 6.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 7.  Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.

Authors:  Michele Mancini; Giampaolo Perna; Andrea Rossi; Antonino Petralia
Journal:  Expert Opin Pharmacother       Date:  2010-05       Impact factor: 3.889

8.  Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies.

Authors:  Daniel K Kajdasz; Smriti Iyengar; Durisala Desaiah; Misha-Miroslav Backonja; John T Farrar; David A Fishbain; Troels S Jensen; Michael C Rowbotham; Christine N Sang; Dan Ziegler; Henry J McQuay
Journal:  Clin Ther       Date:  2007       Impact factor: 3.393

9.  Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings.

Authors:  Alexander M McKinney; James Short; Charles L Truwit; Zeke J McKinney; Osman S Kozak; Karen S SantaCruz; Mehmet Teksam
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

Review 10.  Drug-induced serotonin syndrome: a review.

Authors:  Christina Sun-Edelstein; Stewart J Tepper; Robert E Shapiro
Journal:  Expert Opin Drug Saf       Date:  2008-09       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.